Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer

Vikas Mehta, Tara Moore-Medlin, Jose M. Flores, Xiaohui Ma, Oleksandr Ekshyyan, Cherie Ann O. Nathan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. Study design: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival. Pearson Chi-square tests were used to compare proportions between subgroups. One-way analysis of variance was used to compare the continuous variable age between subgroups. Kaplan-Meier method was used to produce survival curves, and comparisons between survival curves were made using the log-rank test. The survival functions comparing subgroups of chemotherapy were analyzed using semiparametric (i.e. Cox proportional hazards models) and fully parametric regression with Weibull distributions. Multivariable models were adjusted for age at diagnosis, gender, race, chemotherapy, radiotherapy, and cancer stage. Results: In the multivariable analysis, the hazard ratio for cetuximab compared to cisplatin or carboplatin/paclitaxel was HR=0.77[95% CI = 0.67, 0.90] in the HPV - group, suggesting more favorable outcomes for the patients on cetuximab in this group. However, in the HPV + cohort, the hazard ratio was 1.88 [95% CI = 1.42, 2.50] for those patients treated with cetuximab vs platinum-based therapy. Conclusions: Our data suggest that cetuximab may have inferior outcomes in HPV-associated OPSCC compared to traditional platinum-based therapy.

Original languageEnglish (US)
Pages (from-to)70907-70915
Number of pages9
JournalOncotarget
Volume8
Issue number41
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Oropharyngeal Neoplasms
Radiation
Survival
Platinum
Radiotherapy
Drug Therapy
Carboplatin
Chi-Square Distribution
Paclitaxel
Proportional Hazards Models
Cisplatin
Cetuximab
Neoplasms
Analysis of Variance
Therapeutics
Recurrence

Keywords

  • Cetuximab
  • Cisplatin
  • Human papillomavirus
  • Oropharyngeal carcinoma
  • Survival outcomes

ASJC Scopus subject areas

  • Oncology

Cite this

Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer. / Mehta, Vikas; Moore-Medlin, Tara; Flores, Jose M.; Ma, Xiaohui; Ekshyyan, Oleksandr; Nathan, Cherie Ann O.

In: Oncotarget, Vol. 8, No. 41, 2017, p. 70907-70915.

Research output: Contribution to journalArticle

Mehta, Vikas ; Moore-Medlin, Tara ; Flores, Jose M. ; Ma, Xiaohui ; Ekshyyan, Oleksandr ; Nathan, Cherie Ann O. / Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer. In: Oncotarget. 2017 ; Vol. 8, No. 41. pp. 70907-70915.
@article{384c390e44d14fa581f86da7ce3568e4,
title = "Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer",
abstract = "Purpose: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. Study design: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival. Pearson Chi-square tests were used to compare proportions between subgroups. One-way analysis of variance was used to compare the continuous variable age between subgroups. Kaplan-Meier method was used to produce survival curves, and comparisons between survival curves were made using the log-rank test. The survival functions comparing subgroups of chemotherapy were analyzed using semiparametric (i.e. Cox proportional hazards models) and fully parametric regression with Weibull distributions. Multivariable models were adjusted for age at diagnosis, gender, race, chemotherapy, radiotherapy, and cancer stage. Results: In the multivariable analysis, the hazard ratio for cetuximab compared to cisplatin or carboplatin/paclitaxel was HR=0.77[95{\%} CI = 0.67, 0.90] in the HPV - group, suggesting more favorable outcomes for the patients on cetuximab in this group. However, in the HPV + cohort, the hazard ratio was 1.88 [95{\%} CI = 1.42, 2.50] for those patients treated with cetuximab vs platinum-based therapy. Conclusions: Our data suggest that cetuximab may have inferior outcomes in HPV-associated OPSCC compared to traditional platinum-based therapy.",
keywords = "Cetuximab, Cisplatin, Human papillomavirus, Oropharyngeal carcinoma, Survival outcomes",
author = "Vikas Mehta and Tara Moore-Medlin and Flores, {Jose M.} and Xiaohui Ma and Oleksandr Ekshyyan and Nathan, {Cherie Ann O.}",
year = "2017",
doi = "10.18632/oncotarget.20197",
language = "English (US)",
volume = "8",
pages = "70907--70915",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

TY - JOUR

T1 - Survival outcomes based on systemic agent used concurrently with radiation in human-papillomavirus associated oropharyngeal cancer

AU - Mehta, Vikas

AU - Moore-Medlin, Tara

AU - Flores, Jose M.

AU - Ma, Xiaohui

AU - Ekshyyan, Oleksandr

AU - Nathan, Cherie Ann O.

PY - 2017

Y1 - 2017

N2 - Purpose: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. Study design: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival. Pearson Chi-square tests were used to compare proportions between subgroups. One-way analysis of variance was used to compare the continuous variable age between subgroups. Kaplan-Meier method was used to produce survival curves, and comparisons between survival curves were made using the log-rank test. The survival functions comparing subgroups of chemotherapy were analyzed using semiparametric (i.e. Cox proportional hazards models) and fully parametric regression with Weibull distributions. Multivariable models were adjusted for age at diagnosis, gender, race, chemotherapy, radiotherapy, and cancer stage. Results: In the multivariable analysis, the hazard ratio for cetuximab compared to cisplatin or carboplatin/paclitaxel was HR=0.77[95% CI = 0.67, 0.90] in the HPV - group, suggesting more favorable outcomes for the patients on cetuximab in this group. However, in the HPV + cohort, the hazard ratio was 1.88 [95% CI = 1.42, 2.50] for those patients treated with cetuximab vs platinum-based therapy. Conclusions: Our data suggest that cetuximab may have inferior outcomes in HPV-associated OPSCC compared to traditional platinum-based therapy.

AB - Purpose: To investigate survival outcomes of patients treated with concurrent cetuximab and radiotherapy for primary management of both HPV positive and negative OPSCC, and compare the results to traditional platinum-based therapy. We hypothesize that the use of cetuximab in the HPV positive OPSCC patients will result in inferior survival based on tumor biological differences. Study design: A single institution retrospective analysis of 304 patients. The primary outcomes of interest were 1) overall survival and 2) relapse free survival. Pearson Chi-square tests were used to compare proportions between subgroups. One-way analysis of variance was used to compare the continuous variable age between subgroups. Kaplan-Meier method was used to produce survival curves, and comparisons between survival curves were made using the log-rank test. The survival functions comparing subgroups of chemotherapy were analyzed using semiparametric (i.e. Cox proportional hazards models) and fully parametric regression with Weibull distributions. Multivariable models were adjusted for age at diagnosis, gender, race, chemotherapy, radiotherapy, and cancer stage. Results: In the multivariable analysis, the hazard ratio for cetuximab compared to cisplatin or carboplatin/paclitaxel was HR=0.77[95% CI = 0.67, 0.90] in the HPV - group, suggesting more favorable outcomes for the patients on cetuximab in this group. However, in the HPV + cohort, the hazard ratio was 1.88 [95% CI = 1.42, 2.50] for those patients treated with cetuximab vs platinum-based therapy. Conclusions: Our data suggest that cetuximab may have inferior outcomes in HPV-associated OPSCC compared to traditional platinum-based therapy.

KW - Cetuximab

KW - Cisplatin

KW - Human papillomavirus

KW - Oropharyngeal carcinoma

KW - Survival outcomes

UR - http://www.scopus.com/inward/record.url?scp=85030267194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030267194&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20197

DO - 10.18632/oncotarget.20197

M3 - Article

AN - SCOPUS:85030267194

VL - 8

SP - 70907

EP - 70915

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -